The European Commission says the collective actions it is proposing should allow it to work more closely with the pharmaceutical industry and help EU member states improve the security of medicines supply.
The European Commission has published a list of short- and longer-term actions it says the EU needs to take to address critical medicines shortages and improve the security of supply chains, both generally and in times of health emergencies.
In a communication published on 24 October, the commission proposes a “Critical Medicines List” to be ready by the...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
